These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22573349)

  • 1. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.
    Griffioen AW; Mans LA; de Graaf AMA; Nowak-Sliwinska P; de Hoog CLMM; de Jong TAM; Vyth-Dreese FA; van Beijnum JR; Bex A; Jonasch E
    Clin Cancer Res; 2012 Jul; 18(14):3961-3971. PubMed ID: 22573349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
    Mittal K; Koon H; Elson P; Triozzi P; Dowlati A; Chen H; Borden EC; Rini BI
    Cancer Biol Ther; 2014 Aug; 15(8):975-81. PubMed ID: 24842548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.
    Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V
    Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
    Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
    Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.
    Bruce JY; Kolesar JM; Hammers H; Stein MN; Carmichael L; Eickhoff J; Johnston SA; Binger KA; Heideman JL; Perlman SB; Jeraj R; Liu G
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):485-93. PubMed ID: 24414551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.
    Nowak-Sliwinska P; van Beijnum JR; Griffioen CJ; Huinen ZR; Sopesens NG; Schulz R; Jenkins SV; Dings RPM; Groenendijk FH; Huijbers EJM; Thijssen VLJL; Jonasch E; Vyth-Dreese FA; Jordanova ES; Bex A; Bernards R; de Gruijl TD; Griffioen AW
    Angiogenesis; 2023 May; 26(2):279-293. PubMed ID: 36459240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
    Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ
    Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
    Sato M; Nakai Y; Nakata W; Yoshida T; Hatano K; Kawashima A; Fujita K; Uemura M; Takayama H; Nonomura N
    PLoS One; 2013; 8(9):e74313. PubMed ID: 24073208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
    Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
    PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.